专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014091388A3 BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT 审中-公开
标题翻译：生物标志物对阿尔法7烟碱乙酰胆碱受体激活剂治疗反应的预测
公开(公告)号：WO2014091388A3
公开(公告)日：2014-08-21
申请号：PCT/IB2013060744
申请日：2013-12-09
申请人： NOVARTIS AG , FEUERBACH DOMINIK , GOMEZ-MANCILLA BALTAZAR , HE YUNSHENG , JOHNS DONALD , LOPEZ-LOPEZ CRISTINA , MCALLISTER KEVIN HALL , PEZOUS NICOLE , SANDFORD LISA , WEISS MARKUS
发明人： FEUERBACH DOMINIK , GOMEZ-MANCILLA BALTAZAR , HE YUNSHENG , JOHNS DONALD , LOPEZ-LOPEZ CRISTINA , MCALLISTER KEVIN HALL , PEZOUS NICOLE , SANDFORD LISA , WEISS MARKUS
IPC分类号： A61K45/06 , A61K31/44 , A61K31/4748 , A61P25/28
CPC分类号： C12Q1/6883 , A61K9/1623 , A61K9/1652 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K9/2086 , A61K9/4858 , A61K9/4866 , A61K31/439 , A61K31/444 , A61K45/06 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , A61K2300/00
摘要： The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.
摘要翻译：本发明提供了用于预测患有认知障碍或功能障碍，精神病和/或神经退行性障碍的对象对α7烟碱乙酰胆碱受体激活剂治疗的治疗反应性的方法。

2. 发明申请

WO2011009890A2 USE OF AZABICYCLOALKYL DERIVATIVES OR PYRROLIDINE-2-ONE DERIVATIVES 审中-公开
标题翻译：异恶唑烷酮衍生物或吡咯烷-2-酮衍生物的应用
公开(公告)号：WO2011009890A2
公开(公告)日：2011-01-27
申请号：PCT/EP2010060571
申请日：2010-07-21
申请人： NOVARTIS AG , FEUERBACH DOMINIK , GOMEZ-MANCILLA BALTAZAR
发明人： FEUERBACH DOMINIK , GOMEZ-MANCILLA BALTAZAR
IPC分类号： A61K31/439
CPC分类号： A61K31/439 , A61K31/444 , A61K31/501 , A61K31/506
摘要： The invention concerns the use of azabicydoalkyl derivatives or pyrroiidine-2-one derivatives for the treatment, prevention or delay of progression of ataxia.
摘要翻译：本发明涉及氮杂二烷基衍生物或吡咯烷-2-酮衍生物用于治疗，预防或延缓共济失调进展。

3. 发明申请

WO2007149798A2 BIOMARKERS FOR THE PROGRESSION OF ALZHEIMER'S DISEASE 审中-公开
标题翻译：生物标志物对阿尔茨海默病的进展
公开(公告)号：WO2007149798A2
公开(公告)日：2007-12-27
申请号：PCT/US2007071421
申请日：2007-06-18
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , HE YUNSHENG , GOMEZ-MANCILLA BALTAZAR , MEYER JOANNE , ROVELLI GIORGIO , KUHN RAINER R , BILBE GRAEME
发明人： HE YUNSHENG , GOMEZ-MANCILLA BALTAZAR , MEYER JOANNE , ROVELLI GIORGIO , KUHN RAINER R , BILBE GRAEME
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： The genetic polymorphism LRRK2 (leucine-rich repeat kinase 2)-T1602S is significantly associated with conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD), with the patients with TT genotype being at greater risk to progress to Alzheimer's disease. The LRRK2-T2352 also showed a trend for conversion to Alzheimer's disease, with the patients with CC genotype tending to progress to Alzheimer's disease. Similar to the APOE-E4 allele, in the presence of a BuChE-K variant, LRRK2-T1602S and LRRK2-T2352 showed a greater association with the rate of conversion from mild cognitive impairment to Alzheimer's disease. In another study with placebo-treated Alzheimer's disease patients, LRRK2-T1602S and LRRK2-T2352 showed a same trend of association. The Alzheimer's disease patients with TT genotype of LRRK2-T1602S or CC genotype of LRRK2-T2352 tended to decline faster on cognitive performance over 6 months, especially in the presence of a BuChE-K variant. The association between the two common LRRK2 polymorphisms and Alzheimer's disease progression shows that LRRK2 may play a role in Alzheimer's disease pathogenesis, especially disease progression, and that polymorphisms of LRRK2 can be used as biomrkers of this progression.
摘要翻译：遗传多态性LRRK2（富含亮氨酸的重复激酶2）-T1602S与轻度认知障碍（MCI）与阿尔茨海默病（AD）的转化显着相关，TT基因型患者进入阿尔茨海默氏病的风险更大。 LRRK2-T2352也显示出转化为阿尔茨海默病的趋势，CC基因型患者往往进展为阿尔茨海默氏病。与APOE-E4等位基因相似，在BuChE-K变体存在下，LRRK2-T1602S和LRRK2-T2352显示与从轻度认知障碍转变为阿尔茨海默氏病的速率更大的关联。在安慰剂治疗的阿尔茨海默病患者的另一项研究中，LRRK2-T1602S和LRRK2-T2352显示出相同的关联趋势。具有LRRK2-T1602S的TT基因型或LRRK2-T2352的CC基因型的阿尔茨海默氏病患者在6个月以上的认知功能上往往更快下降，特别是在存在BuChE-K变体的情况下。两种常见的LRRK2多态性与阿尔茨海默病进展的关系表明，LRRK2可能在阿尔茨海默氏病发病机制中发挥重要作用，特别是疾病进展，LRRK2的多态性可作为这一进展的生物学家。

4. 发明申请

WO2009047303A2 ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物
公开(公告)号：WO2009047303A2
公开(公告)日：2009-04-16
申请号：PCT/EP2008063553
申请日：2008-10-09
申请人： NOVARTIS AG , UMBRICHT DANIEL , GOMEZ-MANCILLA BALTAZAR
发明人： UMBRICHT DANIEL , GOMEZ-MANCILLA BALTAZAR
IPC分类号： A61K31/4427 , A61P25/00 , A61P43/00
CPC分类号： A61K31/4427
摘要： The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of a pervasive developmental disorder. The invention further concerns the use of an mGluR modulator for the treatment, prevention or delay of progression of a disorder is selected from Fragile X syndrome and fragile X- associated tremor/ataxia syndrome (FXTAS).
摘要翻译：本发明涉及使用mGluR调节剂，例如，一种mGluR5调节剂，用于治疗，预防或延缓普遍性发育障碍的进展。本发明还涉及使用mGluR调节剂来治疗，预防或延缓疾病进展，其选自脆性X综合征和脆性X联合震颤/共济失调综合征（FXTAS）。

5. 发明申请

WO2010000763A3 COMBINATIONS COMPRISING MGLUR MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE 审中-公开
标题翻译：包括用于治疗帕金森病的MGLUR调节剂的组合
公开(公告)号：WO2010000763A3
公开(公告)日：2010-02-25
申请号：PCT/EP2009058230
申请日：2009-06-30
申请人： NOVARTIS AG , GOMEZ-MANCILLA BALTAZAR , GASPARINI FABRIZIO
发明人： GOMEZ-MANCILLA BALTAZAR , GASPARINI FABRIZIO
IPC分类号： A61K31/404 , A61K31/4427 , A61K31/4545 , A61K31/465 , A61K31/4709 , A61K31/4725 , A61K45/06 , A61P25/16
CPC分类号： A61K31/5377 , A61K31/12 , A61K31/165 , A61K31/198 , A61K31/404 , A61K31/405 , A61K31/428 , A61K31/437 , A61K31/4427 , A61K31/444 , A61K31/4545 , A61K31/465 , A61K31/4709 , A61K31/4725 , A61K31/473 , A61K31/4985 , A61K45/06 , A61K2300/00
摘要： The invention concerns the combinations of an mGluR modulator, e.g. an mGluR5 modulator and at least one of L-dopa, a dopamine modulator, e.g. a dopamine agonist, a dopa decarboxylase inhibitor or a catechol-O-methyl transferase inhibitor for use in the treatment of Parkinson's Disease and/or associated disorders.
摘要翻译：本发明涉及mGluR调节剂的组合，例如 mGluR5调节剂和L-多巴，多巴胺调节剂中的至少一种。多巴胺激动剂，多巴脱羧酶抑制剂或儿茶酚-O-甲基转移酶抑制剂，用于治疗帕金森病和/或相关疾病。

6. 发明申请

WO2009047296A2 ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物
公开(公告)号：WO2009047296A2
公开(公告)日：2009-04-16
申请号：PCT/EP2008063544
申请日：2008-10-09
申请人： NOVARTIS AG , UMBRICHT DANIEL , GOMEZ-MANCILLA BALTAZAR , GASPARINI FABRIZIO , DI PAOLO THERESE
发明人： UMBRICHT DANIEL , GOMEZ-MANCILLA BALTAZAR , GASPARINI FABRIZIO , DI PAOLO THERESE
IPC分类号： A61K31/4427 , A61P25/16
CPC分类号： A61K31/404 , A61K31/165 , A61K31/198 , A61K2300/00
摘要： The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of Parkinson's Disease and associated disorders.
摘要翻译：本发明涉及使用mGluR调节剂，例如，一种用于治疗，预防或延缓帕金森病和相关疾病进展的mGluR5调节剂。

7. 发明申请

WO9959563A2 CABERGOLINE AND PRAMIPEXOLE: NEW USES AND COMBINATIONS 审中-公开
标题翻译： CABBGGININE和PRAMIPEXOLE：新用途和组合
公开(公告)号：WO9959563A2
公开(公告)日：1999-11-25
申请号：PCT/US9907024
申请日：1999-05-07
申请人： UPJOHN CO , GOMEZ MANCILLA BALTAZAR
发明人： GOMEZ-MANCILLA BALTAZAR
IPC分类号： A61K31/425 , A61K31/428 , A61K31/435 , A61K31/437 , A61K31/44 , A61K31/48 , A61P25/00 , A61P25/16 , A61P43/00 , A61K31/00
CPC分类号： A61K31/435 , A61K31/425 , A61K31/428 , A61K31/437 , A61K31/44 , A61K31/48 , A61K2300/00
摘要： This invention discloses new uses and treatments involving cabergoline, pramipexole and new combinations of cabergoline plus pramipexole used to treat patients. Here we disclose the use of cabergoline or pramipexole to treat PSP and MSA. Also disclosed is a combination treatment of cabergoline and pramipexole provided concurrently to a patient in need thereof for the treatment of various central nervous system diseases and in particular for the treatment of Parkinson's Disease (PD), but also for PSP and MSA.
摘要翻译：本发明公开了涉及卡麦角林，普拉克索和用于治疗患者的卡麦角林加普拉克索的新组合的新用途和治疗。在这里我们公开使用卡麦角林或普拉克索治疗PSP和MSA。还公开了与需要其治疗各种中枢神经系统疾病，特别是治疗帕金森病（PD），以及PSP和MSA的治疗同时提供的卡麦角林和普拉克索的组合治疗。

8. 发明专利

AU2012232711B2 Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease 未知
公开(公告)号：AU2012232711B2
公开(公告)日：2016-04-28
申请号：AU2012232711
申请日：2012-03-16
申请人： JOHNS DONALD , NOVARTIS AG
发明人： DI PAOLO THERESE , FEUERBACH DOMINIK , GOMEZ-MANCILLA BALTAZAR , LOPEZ-LOPEZ CRISTINA , JOHNS DONALD , GASPARINI FABRIZIO
IPC分类号： A61K31/44 , A61K31/4748 , A61K45/06 , A61P25/16
摘要： The present invention relates to novel combinations suitable for the treatment of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease, which comprise, as active ingredients, at least one low molecular weight nicotinic acetylcholine receptor alpha 7 activator and at least one low molecular weight metabotropic glutamate receptor 5 antagonist; to their preparation; to their use as medicaments and to medicaments comprising them.

9. 发明专利

AU2012232711A1 Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease 未知
公开(公告)号：AU2012232711A1
公开(公告)日：2013-10-03
申请号：AU2012232711
申请日：2012-03-16
申请人： JOHNS DONALD , NOVARTIS AG
发明人： DI PAOLO THERESE , FEUERBACH DOMINIK , GOMEZ-MANCILLA BALTAZAR , LOPEZ-LOPEZ CRISTINA , JOHNS DONALD
IPC分类号： A61K31/44 , A61K31/4748 , A61K45/06 , A61P25/16
摘要： The present invention relates to novel combinations suitable for the treatment of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease, which comprise, as active ingredients, at least one low molecular weight nicotinic acetylcholine receptor alpha 7 activator and at least one low molecular weight metabotropic glutamate receptor 5 antagonist; to their preparation; to their use as medicaments and to medicaments comprising them.

10. 发明申请

WO2013057687A3 BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT 审中-公开
标题翻译：生物标志物对ALPHA的反应预测7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT
公开(公告)号：WO2013057687A3
公开(公告)日：2013-07-11
申请号：PCT/IB2012055692
申请日：2012-10-18
申请人： NOVARTIS AG
发明人： FEUERBACH DOMINIK , GOMEZ-MANCILLA BALTAZAR , HE YUNSHENG , JOHNS DONALD , LOPEZ-LOPEZ CRISTINA , MCALLISTER KEVIN HALL , PEZOUS NICOLE , SANDFORD LISA , WEISS MARKUS
IPC分类号： A61K31/44 , A61P25/28
CPC分类号： A61K31/439 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156
摘要： The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.
摘要翻译：本发明提供了用于预测患有认知障碍或功能障碍，精神病和/或神经变性疾病对α7烟碱乙酰胆碱受体激活剂治疗的受试者的治疗反应性的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式